Ceftolozane/tazobactam exhibited potent antimicrobial activity when tested against Pseudomonas aeruginosa isolates from US medical centers, including multidrug-resistant strains, a study reported at IDWeek 2013.
In a cohort of pregnant women, no associations were found between the 2010-2011 seasonal influenza infection or vaccination and four common maternal outcomes—gestational hypertension, preeclampsia/eclampsia, gestational diabetes, and chorioamnionitis—a prospective study concluded at IDWeek 2013.
Penicillins may be used with low risk of treatment failure for patients with community-acquired pneumonia (CAP), a case-control study reported at IDWeek 2013 has found.
Treatment with sofosbuvir + peginterferon alfa-2a/ribavirin for 12 weeks in treatment-naïve, HIV/HCV co-infected patients led to a highly effective sustained virologic response rate, results of a study presented at IDWeek 2013.
Week 48 “snapshot analysis” finds two single tablet regimens non-inferior for virologic suppression in treatment-naïve patients with HIV-1 infection, the STaR study reported at IDWeek 2013.
Patients with HIV-1 treated with rilpivirine/emtricitabine/tenofovir DF once-daily single-tablet regimen maintained virologic suppression at 48 weeks regardless of initiation time.
Researchers did not observe a difference in recurrent infections when treated with either clindamycin or trimethoprim-sulfamethoxazole (TMP-SMX) in patients with uncomplicated skin and soft tissue infections (uSSTIs), according to results presented at IDWeek 2013.
Significantly high rates of premature treatment discontinuation was observed in patients treated with either nafcillin or cefazolin, with high rates of drug-related adverse events (DRAE) occurring with nafcillin treatment, as presented at IDWeek 2013.
Elvitegravir/cobicistat/emtricitabine/tenofovir DF was well-tolerated and safe compared with efavirenz/emtricitabine/tenofovir DF in treatment-naïve Black patients with HIV infection, a study presented at IDWeek 2013 has found.
Renal impairment of any kind had no significant impact on the efficacy of daptomycin vs. vancomycin in the treatment of MRSA bacteremia, a study presented at IDWeek 2013 has concluded.
